Biotech and Drug Stocks
7.46k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| Biotech and Drug Stocks | -0.15% | - | - | - |
| ^GSPC | +0.12% | +5.84% | +26.49% | +5602.44% |
31 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 770 | -1.12 | -0.15% | 4:00 p.m. EDT | 1.67M | 2.76M | 731.81B |
| NVO | Novo Nordisk A/S | 131.89 | -1.15 | -0.86% | 4:00 p.m. EDT | 2.59M | 4.58M | 587.55B |
| JNJ | Johnson & Johnson | 154.64 | +0.36 | +0.23% | 4:00 p.m. EDT | 6.52M | 7.42M | 372.17B |
| MRK | Merck & Co., Inc. | 131.19 | +0.31 | +0.24% | 4:00 p.m. EDT | 8.28M | 8.24M | 332.28B |
| ABBV | AbbVie Inc. | 166.42 | +2.07 | +1.26% | 4:00 p.m. EDT | 5.15M | 5.62M | 293.88B |
| AZN | AstraZeneca PLC | 76.9 | -0.14 | -0.18% | 4:00 p.m. EDT | 2.79M | 5.46M | 239.31B |
| RHHBY | Roche Holding AG | 32.81 | +0.16 | +0.49% | 4:00 p.m. EDT | 2.78M | 2.87M | 211.09B |
| NVS | Novartis AG | 102.57 | -0.12 | -0.12% | 4:00 p.m. EDT | 781.51k | 1.60M | 210.24B |
| AMGN | Amgen Inc. | 312.47 | -2.25 | -0.71% | 4:00 p.m. EDT | 1.97M | 2.76M | 167.62B |
| PFE | Pfizer Inc. | 28.64 | -0.28 | -0.97% | 4:01 p.m. EDT | 26.11M | 42.61M | 162.29B |
| SNY | Sanofi | 48.67 | -0.15 | -0.31% | 4:00 p.m. EDT | 838.71k | 1.98M | 122.80B |
| VRTX | Vertex Pharmaceuticals Incorporated | 445.21 | +4.57 | +1.04% | 4:00 p.m. EDT | 1.38M | 1.03M | 114.89B |
| REGN | Regeneron Pharmaceuticals, Inc. | 982.29 | +14.31 | +1.48% | 4:00 p.m. EDT | 386.56k | 456.01k | 108.23B |
| GSK | GSK plc | 44.98 | +0.10 | +0.22% | 4:00 p.m. EDT | 1.88M | 3.14M | 93.80B |
| BMY | Bristol-Myers Squibb Company | 44.03 | -0.08 | -0.18% | 4:00 p.m. EDT | 15.79M | 15.42M | 89.25B |
| GILD | Gilead Sciences, Inc. | 67.72 | -0.14 | -0.21% | 4:00 p.m. EDT | 3.58M | 6.95M | 84.37B |
| ZTS | Zoetis Inc. | 174.06 | +0.35 | +0.20% | 4:00 p.m. EDT | 2.00M | 3.71M | 79.42B |
| MRNA | Moderna, Inc. | 132.9 | +0.22 | +0.17% | 4:00 p.m. EDT | 2.72M | 3.83M | 50.93B |
| TAK | Takeda Pharmaceutical Company Limited | 13.22 | -0.09 | -0.68% | 4:00 p.m. EDT | 1.01M | 1.65M | 41.70B |
| HLN | Haleon plc | 8.51 | +0.14 | +1.67% | 4:00 p.m. EDT | 11.45M | 6.65M | 38.86B |
| BIIB | Biogen Inc. | 230.57 | +0.53 | +0.23% | 4:00 p.m. EDT | 985.06k | 1.23M | 33.57B |
| BAYRY | Bayer Aktiengesellschaft | 7.83 | +0.06 | +0.77% | 4:00 p.m. EDT | 949.73k | 2.08M | 30.77B |
| ARGX | argenx SE | 365.81 | -10.79 | -2.87% | 4:00 p.m. EDT | 110.21k | 270.84k | 22.32B |
| BNTX | BioNTech SE | 90.61 | -2.37 | -2.55% | 4:00 p.m. EDT | 471.78k | 593.47k | 21.84B |
| BGNE | BeiGene, Ltd. | 172.85 | +1.82 | +1.06% | 4:00 p.m. EDT | 275.36k | 215.09k | 19.61B |
| GMAB | Genmab A/S | 29.98 | +0.33 | +1.11% | 4:00 p.m. EDT | 375.16k | 528.15k | 19.36B |
| TEVA | Teva Pharmaceutical Industries Limited | 16.29 | -0.01 | -0.06% | 4:00 p.m. EDT | 7.79M | 10.13M | 18.90B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 149.4 | -1.82 | -1.20% | 4:00 p.m. EDT | 481.25k | 658.99k | 18.90B |
| ALPMY | Astellas Pharma Inc. | 9.48 | -0.20 | -2.07% | 3:59 p.m. EDT | 145.79k | 329.39k | 17.16B |
| RPRX | Royalty Pharma plc | 27.27 | -0.61 | -2.19% | 4:00 p.m. EDT | 1.91M | 2.70M | 16.29B |
Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb
PR NewswireNEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared
Motley FoolThis Stock Just More Than Doubled in 1 Day: Is It a Buy?
The biotech still hasn't lost momentum.
